ONCIMMUNE HOLDINGS PLC

Post-Annual General Meeting Information • Mar 10, 2025

National Storage Mechanism | Additional information

RNS Number : 0495A

Oncimmune Holdings PLC

10 March 2025

Oncimmune Holdings Plc

("Oncimmune" or the "Company")

Result of General Meeting

The General Meeting of Oncimmune Holdings Plc was held at 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT on 10 March 2025 at 11:00 a.m.

All resolutions put to members were passed on a poll. All resolutions were passed as ordinary resolutions.

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 (Report and Accounts)	27,510,816	99.56%	122,242	0.44%	57,398
Resolution 2 (Remuneration Report)	25,826,233	94.66%	1,455,827	5.34%	408,396
Resolution 3 (Appointment of Auditor)	26,465,373	95.75%	1,175,200	4.25%	49,883
Resolution 4 (Remuneration of Auditor)	27,479,703	99.42%	160,870	0.58%	49,883

The full text of each resolution is available in the Notice of General Meeting, published on the Company's website.

For further information:

contact@oncimmune.com

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Ondraya Swanson (Corporate Broking)

+44 (0) 20 7220 0500

Zeus (Joint Broker)

Dominic King

+44 (0)20 3829 5000

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit  www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMUROORVBUOAAR